Clinical Trial Update: Combination of Ibrutinib and As2O3 in the Treatment of CLL [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating the combination of ibrutinib and arsenic trioxide for chronic lymphocytic leukemia; the status is currently unknown.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia

Drugs mentioned

• IMBRUVICA (IBRUTINIB)
• Trisenox (arsenic trioxide)

Snippet

Sponsor: Peking University People's Hospital | Conditions: Leukemia, Lymphocytic, Chronic, B-Cell | Phase 3 | Status: UNKNOWN